Research Products & Services
RiboMed provides bisulfite-free and MSRE-free products and services for the ultra-sensitive & quantitative measurement of DNA methylation, even in FFPE tissues and bodily fluids used for liquid biopsies.
RiboMed’s tests are offered in the CLIA certified/CAP accredited Ribomed Clinical Services Lab.
GliomaSTRAT measures genetic and epigenetic markers involved in brain cancer (glioma, GBM) and includes
(1) MGMT methylation measurement to predict TMZ response and
(2) glioma subtype determination with G-CIMP (glioma CpG island methylator phenotype) assignment and IDH1 WT and R132H mutation analysis.
Both multi-gene DNA methylation and mutational analysis in one assay with nanograms of DNA.
Physicians & Clinical Trial Customers:
To order the GliomaSTRAT test or any of its component parts (MGMT, IDH1 WT/R132H, G-CIMP) for analysis in Ribomed’s CLIA laboratory, contact Ribomed Clinical Services Lab. firstname.lastname@example.org.
RiboMed CEO to speak at 5th Cancer Epigenetics Conference in San Francisco Nov 9, part of the Novel Cancer Therapeutics Summit.
Ribomed and Tocagen collaborate to analyze epigenetic prognostic markers including MGMT in recurrent brain tumors
Study Published in Science Translational Medicine reports favorable Safety and Extended Survival for Brain cancer Patients Treated with Tocagen’s Cancer-Selective Viral Gene Therapy